Accenture Services Pvt
Accenture Services Pvt is recorded as a service provider in 19 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 19 of 19 trials · Latest update first
A Randomized, Phase 2/3 Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-Paclitaxel and Gemcitabine versus Placebo in Combination With Nab-Paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants with Advanced Solid Tumors
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer
Sponsor Bristol Myers Squibb International Corporation
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- Enrollment ranged from 1 participant in Austria to 97 in Spain; 337 of 769 participants were enrolled in EEA countries.
These findings describe the trial, not the service provider’s performance or responsibility.
A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
Phase 1/2 Open-label Study of BMS-986466 in Combination with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Advanced Solid Tumors
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Not reported
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- Only the Part 1 drug-drug interaction arm enrolled participants; no participants enrolled in Part 1A/1B dose escalation or Part 2A/2B dose expansion.
- Enrollment occurred in Australia (1 participant) and the United States (4 participants), with no participants enrolled in the EEA.
- A global protocol amendment required participants with actionable mutations to have received an approved targeted therapy for that mutation, if available, to be eligible.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma who have Received at least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-label, Randomized, Noninferiority Trial of the Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Had Received Prior Systemic Therapy
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma
Sponsor Celgene Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer (CheckMate 77T, CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 77T)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Placebo-controlled, Global Proof-of-concept Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease (TargetTau-1)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
CA209-8HW A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Sponsor Bristol Myers Squibb International Corporation
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Sponsor Bristol Myers Squibb International Corporation
- Start (EU)
- Latest update
- Estimated end
A Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment with Subcutaneous Abatacept vs Adalimumab, on Background Methotrexate, in Adults with Early, Seropositive Rheumatoid Arthritis Who Have "Shared Epitope" HLA Class II Risk Alleles and Have an Inadequate Response to Methotrexate
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers
Sponsor Bristol Myers Squibb International Corporation
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Sponsor Bristol Myers Squibb International Corporation
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Accenture Services Pvt?
The 2026-10-09 snapshot links Accenture Services Pvt to 19 distinct CTIS trials. Recorded services include Safety reporting & pharmacovigilance, Data management, submission administrative support, Adverse event case data entry and medical review, among 7 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Accenture Services Pvt?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gastroenterology, Haematological Malignancies, Dermatology. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Accenture Services Pvt conducted?
The linked trials record locations in 21 countries, including Spain, France, Italy, Germany, Poland. These are trial locations, not confirmed office locations or countries where Accenture Services Pvt delivered services.
What can this page tell me about Accenture Services Pvt's trial experience?
Browse 19 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Accenture Services Pvt. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Accenture Services Pvt. Ltd.